Hematologic and cytogenetic responses
. | 3 mo . | 6 mo . | 9 mo . | 12 mo . |
|---|---|---|---|---|
| No. of patients at risk | 30 | 30 | 30 | 30 |
| Complete hematologic response (95% CI) | 30* | 30 | 30 | 29 |
| 100% (88-100) | 100% (88-100) | 100% (88-100) | 97% (83-100) | |
| Cytogenetic response | ||||
| Major | 21 | 22 | 23 | 25 |
| 70% (51-85) | 73% (54-88) | 77% (58-90) | 83% (65-94) | |
| Complete | 7 | 17 | 16 | 21 |
| 23% (10-42) | 57% (37-75) | 53% (34-72) | 70% (51-85) | |
| Partial | 14 | 5 | 7 | 4 |
| 47% (28-66) | 17% (10-42) | 23% (10-42) | 13% (4-31) | |
| Minor | 2 | 3 | 2 | 2 |
| Failure | 2 | 2 | 1 | 1 |
| Not assessable† | 5 | 3 | 4 | 2 |
. | 3 mo . | 6 mo . | 9 mo . | 12 mo . |
|---|---|---|---|---|
| No. of patients at risk | 30 | 30 | 30 | 30 |
| Complete hematologic response (95% CI) | 30* | 30 | 30 | 29 |
| 100% (88-100) | 100% (88-100) | 100% (88-100) | 97% (83-100) | |
| Cytogenetic response | ||||
| Major | 21 | 22 | 23 | 25 |
| 70% (51-85) | 73% (54-88) | 77% (58-90) | 83% (65-94) | |
| Complete | 7 | 17 | 16 | 21 |
| 23% (10-42) | 57% (37-75) | 53% (34-72) | 70% (51-85) | |
| Partial | 14 | 5 | 7 | 4 |
| 47% (28-66) | 17% (10-42) | 23% (10-42) | 13% (4-31) | |
| Minor | 2 | 3 | 2 | 2 |
| Failure | 2 | 2 | 1 | 1 |
| Not assessable† | 5 | 3 | 4 | 2 |